{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:54:32Z","timestamp":1778774072234,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The increasing use of sodium glucose transporter 2 inhibitors (SGLT2i) for treating cardiovascular (CV) diseases and type 2 diabetes (T2D) is accompanied by a rise in euglycemic diabetic ketoacidosis occurrences in cardiac surgery patients. Patients undergoing cardiac surgery, due to their pre-existing CV\u00a0disease which often requires SGLT2i prescriptions, face an increased risk of postoperative metabolic acidosis (MA) or ketoacidosis (KA) associated with SGLT2i, compounded by fasting and surgical stress. The primary aim of this study is to quantify the incidence of SGLT2i-related postoperative MA or KA and to identify related risk factors. We analyzed data retrospectively of 823 cardiac surgery patients, including 46 treated with SGLT2i from November 2019 to October 2022. Among 46 final cohorts treated preoperatively with SGLT2i, 29 (63%) developed postoperative metabolic complications. Of these 46 patients, stratified into two categories based on postoperative laboratory findings, risk factor analysis were conducted and compared. Analysis indicated a prescription duration over one week significantly elevated the risk of complications (Unadjusted OR, 11.7; p\u2009=\u20090.032*; Adjusted OR, 31.58; p\u2009=\u20090.014*). A subgroup analysis showed that a cardiopulmonary bypass duration of 60\u00a0min or less significantly raises the risk of SGLT2i-related postoperative MA in patients with a sufficient prescription duration. We omitted the term \"diabetes\" in describing complications related to SGLT2i, as these issues are not exclusive to T2D patients. Awareness of SGLT2i-related postoperative MA or KA can help clinicians distinguish between non-life-threatening conditions and severe causes, thereby preventing unnecessary tests and ensuring best practice.<\/jats:p>","DOI":"10.1038\/s41598-024-58853-7","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T07:01:36Z","timestamp":1712386896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Missed postoperative metabolic acidosis associated with sodium-glucose transporter 2 inhibitors in cardiac surgery patients: a retrospective analysis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0648-948X","authenticated-orcid":false,"given":"Hyeon A","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5661-1068","authenticated-orcid":false,"given":"Joo Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-3102","authenticated-orcid":false,"given":"Young Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-2178","authenticated-orcid":false,"given":"Young Tak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0892-4107","authenticated-orcid":false,"given":"Pyo Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"issue":"21","key":"58853_CR1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JV McMurray","year":"2019","unstructured":"McMurray, J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"58853_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383(15), 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"58853_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385(16), 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"58853_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387(12), 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"58853_CR5","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42(36), 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"issue":"5","key":"58853_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","volume":"28","author":"AH Paul","year":"2022","unstructured":"Paul, A. H. et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J. Card. Fail. 28(5), e1\u2013e167 (2022).","journal-title":"J. Card. Fail."},{"issue":"13","key":"58853_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jama.2022.3970","volume":"327","author":"HD Larkin","year":"2022","unstructured":"Larkin, H. D. FDA expands empagliflozin heart failure indication. JAMA 327(13), 1219\u20131219. https:\/\/doi.org\/10.1001\/jama.2022.3970 (2022).","journal-title":"JAMA"},{"issue":"12","key":"58853_CR8","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","volume":"65","author":"E Marilly","year":"2022","unstructured":"Marilly, E. et al. SGLT2 inhibitors in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia 65(12), 2000 (2022).","journal-title":"Diabetologia"},{"issue":"9","key":"58853_CR9","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/dom.14075","volume":"22","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 22(9), 1619 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"58853_CR10","unstructured":"FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Food and Drug Administration. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm (2021)."},{"key":"58853_CR11","first-page":"167","volume-title":"Diabetic Emergencies: Ketoacidosis, Hyperglycemic Hyperosmolar State, and Hypoglycemia","author":"G Heidi","year":"2020","unstructured":"Heidi, G. & David, W. L. Endocrine emergencies. In Diabetic Emergencies: Ketoacidosis, Hyperglycemic Hyperosmolar State, and Hypoglycemia 5th edn (eds Heidi, G. & David, W. L.) 167\u2013182 (Elsevier, 2020).","edition":"5"},{"issue":"9","key":"58853_CR12","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters, A. L. et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38(9), 1687 (2015).","journal-title":"Diabetes Care"},{"issue":"23","key":"58853_CR13","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick, M., Chneeweiss, S. & Patorno, E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N. Engl. J. Med. 376(23), 2300 (2017).","journal-title":"N. Engl. J. Med."},{"key":"58853_CR14","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda, P. et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study. BMJ 363, k4365 (2018).","journal-title":"BMJ"},{"key":"58853_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bja.2019.03.028","volume":"123","author":"V Thiruvenkatarajan","year":"2019","unstructured":"Thiruvenkatarajan, V. et al. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: A systematic review. Br. J. Anaesth. 123, 27\u201336 (2019).","journal-title":"Br. J. Anaesth."},{"key":"58853_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2924","author":"JE Blau","year":"2017","unstructured":"Blau, J. E., Tella, S. H., Taylor, S. I. & Rother, K. I. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab. Res. Rev. https:\/\/doi.org\/10.1002\/dmrr.2924 (2017).","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"4","key":"58853_CR17","doi-asserted-by":"publisher","first-page":"460","DOI":"10.4103\/aca.aca_47_21","volume":"25","author":"KB Murugesan","year":"2022","unstructured":"Murugesan, K. B., Balakrishnan, S., Arul, A., Ramalingam, S. & Srinivasan, M. A retrospective analysis of the incidence, outcome and factors associated with the occurrence of euglycemic ketoacidosis in diabetic patients on sodium glucose co-transporter\u20142 inhibitors undergoing cardiac surgery. Ann. Card. Anaesth. 25(4), 460\u2013465 (2022).","journal-title":"Ann. Card. Anaesth."},{"key":"58853_CR18","volume-title":"Euglycemic Diabetic Ketoacidosis","author":"MC Plewa","year":"2022","unstructured":"Plewa, M. C., Bryant, M. & King-Thiele, R. Euglycemic Diabetic Ketoacidosis (StatPearls Publishing, 2022)."},{"issue":"3","key":"58853_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0022-5223(19)42215-0","volume":"61","author":"TAH English","year":"1971","unstructured":"English, T. A. H., Stan, D. & Kirklin, J. W. Changes in colloid osmotic pressure during and shortly after open intracardiac operation. J. Thorac. Cardiovasc. Surg. 61(3), 338\u2013341 (1971).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"58853_CR20","volume-title":"Manual of Perioperative Care in Adult Cardiac Surgery","author":"RM Bojar","year":"2020","unstructured":"Bojar, R. M. Manual of Perioperative Care in Adult Cardiac Surgery 6th edn. (Wiley, 2020).","edition":"6"},{"key":"58853_CR21","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2337\/dc15-1251","volume":"38","author":"E Ngozi","year":"2015","unstructured":"Ngozi, E., Mehul, D., Kirk, W. & Gary, M. Diabetic ketoacidosis and related events in the Canagliflozin type 2 diabetes clinical program. Diabetes Care 38, 1680\u20131686 (2015).","journal-title":"Diabetes Care"},{"issue":"22","key":"58853_CR22","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B., Wanner, C. & Lachin, J. M. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"key":"58853_CR23","doi-asserted-by":"publisher","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi, Q. et al. Benefits and harms of drug treatment for type 2 diabetes: Systematic review and network meta-analysis of randomized controlled trials. BMJ 381, e074068 (2023).","journal-title":"BMJ"},{"issue":"6","key":"58853_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","volume":"173","author":"A Douros","year":"2020","unstructured":"Douros, A. et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: A multicenter cohort study. Ann. Intern. Med. 173(6), 417\u2013425 (2020).","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"58853_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Y Handelsman","year":"2016","unstructured":"Handelsman, Y. et al. American association of clinical endocrinologists and American college of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr. Pract. 22(6), 753\u2013762 (2016).","journal-title":"Endocr. Pract."},{"issue":"Suppl 2","key":"58853_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.13611","volume":"21","author":"D Fitchett","year":"2019","unstructured":"Fitchett, D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes. Metab. 21(Suppl 2), 34\u201342 (2019).","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"58853_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","volume":"7","author":"W Ogawa","year":"2016","unstructured":"Ogawa, W. & Sakaguchi, K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. J. Diabetes Investig. 7(2), 135\u2013138 (2016).","journal-title":"J. Diabetes Investig."},{"issue":"4","key":"58853_CR28","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1053\/j.ajkd.2021.02.341","volume":"78","author":"AZ Fenves","year":"2021","unstructured":"Fenves, A. Z. & Emmett, M. Approach to patients with high anion gap metabolic acidosis: Core curriculum 2021. Am. J. Kidney Dis. 78(4), 590\u2013600 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"58853_CR29","volume-title":"Farxiga (Dapagliflozin) [Prescribing Information]","author":"DE Wilmington","year":"2023","unstructured":"Wilmington, D. E. Farxiga (Dapagliflozin) [Prescribing Information] (AstraZeneca Pharmaceuticals LP, 2023)."},{"key":"58853_CR30","volume-title":"Jardiance (Empagliflozin) [Prescribing Information]","author":"CT Ridgefield","year":"2023","unstructured":"Ridgefield, C. T. Jardiance (Empagliflozin) [Prescribing Information] (Boehringer Ingelheim Pharmaceuticals Inc, 2023)."},{"issue":"2","key":"58853_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12630-017-1018-6","volume":"65","author":"A Lau","year":"2018","unstructured":"Lau, A. et al. Perioperative implications of sodium-glucose cotransporter-2 inhibitors: A case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery. Can. J. Anaesth. 65(2), 188\u2013193 (2018).","journal-title":"Can. J. Anaesth."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58853-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T07:02:51Z","timestamp":1712386971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58853-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["58853"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-58853-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8087"}}